Alufluoride Ltd

Director continuance

• Special Resolution to continue Sri Yugandhar Meka as Non-Executive Independent Director.
• Outcome: Approved with 99.71% in favour and 0.29% against (valid votes: 45,60,328).
• Term: not disclosed; independence status: Non-Executive Independent Director.

NSE admission to trading

• NSE circular 1355/2026 permits ALUFLUOR to trade on NSE Capital Market from Aug 17, 2026.
• ALUFLUOR shares are already listed on BSE and will trade on NSE under the Permitted to Trade category.
• The filing confirms no change to overall listing status; NSE trading is an additional venue.
• Company Secretary Vaishali Kohli signs the filing; circular copy enclosed.

Business overview

• Primary business: recover FSA to produce Aluminium Fluoride (AlF3) flux.
• Customers Hindalco, Vedanta and NALCO dominate primary smelters.
• Installed capacity 24,000 TPA at Visakhapatnam; 4x1 MW captive solar.
• Expansion plans via Alufluoride International Singapore to access overseas markets.
• Pursuing qualification of additional buyers to widen the customer base.

Operational highlights

• Q1 FY27 revenue 326.6 Cr; YoY -39%, QoQ -49%.
• FSA supply disruption due to US-Iran conflict; resolved 15 July 2026.
• May 2026 contract finalisations with price protection.
• New suppliers: Coromandel Kakinada from April 2026; IFFCO Paradeep upgrading fluorine recovery.
• Paradeep Phosphates volumes supplement as available.
• Visakhapatnam plant's final capacity expansion targeted by June 2026.
• Overseas expansion: Alufluoride International Singapore ongoing.

Financial performance

• Revenue 326.6 Cr; YoY -39%; QoQ -49%.
• EBITDA 6.9 Cr; pre-OI margin 17.1%.
• PAT 22.7 Cr; YoY -12%; QoQ -41%.
• EPS 3.51; tax rate 17.4% (vs 30.3% prior year).
• Other income 2.4 Cr; treasury gains cushion profits.
• FY26 final dividend of 34 per share approved.

Strategic priorities & outlook

• Expand buyer base; qualify additional buyers; grow overseas via Singapore.
• FSA supply expected to improve as operations normalise in coming quarters.
• Leverage waste-to-wealth model to lower imports and carbon footprint.

Risks & mitigation

• Geopolitical FSA disruption risk; mitigated by price protection and supplier diversification.
• FSA supply constraints impacted volumes; normalisation expected mid-2026.

Governance & leadership

• No board or management changes reported in this update.

Financial highlights

• Consolidated PAT for Q1FY27: INR 2.7 crore, down 12% YoY.
• Consolidated revenue: INR 26.6 crore; EBITDA: INR 6.9 crore.
• Standalone revenue: INR 26.6 crore; standalone EBITDA: INR 7.0 crore.
• EPS (basic/diluted): INR 3.51; down 12% YoY.
• Income mix: Aluminium Fluoride operations INR 26.0 crore; other income INR 2.4 crore.

Operational / capacity update

• Final expansion completed in June 2026; installed capacity now 24,000 TPA.
• FSA supply issue resolved on 15 July 2026; Visakhapatnam operations restored to normal.
• Volumes expected to improve from Q2 FY27 as FSA availability increases.
• Captive solar capacity up to 4.1 MW; switch to piped natural gas underway.
• Supplier base broadened; Coromandel Kakinada and IFFCO Paradeep contracts strengthened.
• FY26 final dividend INR 4.00 per share approved at AGM 16 July 2026.

Standalone results

• Standalone Q1 FY27 revenue from operations ₹25.97 cr; total income ₹28.93 cr; net profit ₹2.88 cr.
• Earnings per share (basic/diluted) ₹3.68 for the quarter.
• Silicic acid supply disruption reduced volumes; improvement expected from current quarter.

Consolidated results

• Consolidated total income ₹28.93 cr; net profit ₹2.75 cr.
• Consolidated PBT ₹3.32 cr; tax ₹0.57 cr; net profit ₹2.75 cr.
• Earnings per share (consolidated) basic ₹3.97; diluted ₹3.97.
• Overseas subsidiary Alufluoride International PTE Ltd Singapore included; results not reviewed; not material.

Operations & outlook

• Silicic acid disruption impacted both standalone and consolidated performance.
• Completed project expansion; improved FSA supply expected to boost production and revenue in coming quarters.
• No segment reporting; company operates a single inorganic chemical product line.

Business & segments

• Business: inorganic chemical manufacturing; single product line.

Meeting Details

• Board meeting scheduled for 11 August 2026; time and venue not disclosed.

Key Agenda Items

• Consider and approve unaudited standalone and consolidated financial results for quarter ended 30 June 2026.

Other Notes

• Trading window to remain closed until 48 hours after the unaudited results for quarter ended 30 June 2026.

AGM details

• AGM held on 16 July 2026 via VC/OAVM.
• Remote e-voting and venue voting used; Scrutinizer appointed.

Resolutions and outcomes

• Adopt standalone and consolidated financial statements; passed with 1 vote against.
• Final dividend approved; per-share amount not disclosed; passed with 1 vote against.
• Director re-appointment approved; opposed by 89 votes.
• Cost Auditors’ remuneration approved; 2 votes against.
• Remuneration for Managing Director approved; 63 votes against.
• Remuneration for WD/CEO approved; 96 votes against.

AGM details

• AGM held on 16 July 2026 at 11:00 IST via VC/OAVM.

Voting window

• Remote e-voting ran 13 July 2026 10:00 IST to 15 July 2026 17:00 IST.

Ordinary resolutions

• Adoption of standalone financial statements; passed.
• Adoption of consolidated financial statements; passed.
• Final dividend declared for the financial year; passed.
• Re-appointment of Jyothsana Akkineni by rotation; passed.

Special resolutions

• Remuneration of Cost Auditors for 2025-26; passed.
• Remuneration payable to Managing Director; passed.
• Increase in remuneration to Aditya Akkineni, WTD/CEO; passed.

Directors/Remunerations

• Director re-appointment by rotation (Jyothsana Akkineni) approved.

Auditors

• Cost Auditors' remuneration approved for 2025-26.

Operational update

• Raw material supply for Hydrofluosilicic Acid restored, enabling normal production at Visakhapatnam plant.
• Supplier increased plant load and the company will procure requisite quantities.
• Operations are being restored to normal levels per supplier communication dated July 15, 2026.
• Previously reduced operations due to hydrofluosilicic acid supply disruption from Middle East conflict.
• No financial metrics disclosed in this update.

Final dividend proposal

• 💰 Final dividend for financial year 2025-2026 may be recommended.
• 📌 Subject to approval by the Board of Directors.